Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Cessatech ASXSAT:CESSA +3.48%28 PB Ratio is 21.31 as of Aug. 04, 2026, which is 12% below its 10-year median of 24.11. GuruFocus rates XSAT:CESSA with a GF Score™ of 28/100. The stock has 2 warning signs investors should review. Among 1,228 Biotechnology companies, Cessatech AS ranks worse than 94.14% on this metric.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. As of today (2026-08-04), Cessatech AS's share price is kr10.40. Cessatech AS's Book Value per Share for the quarter that ended in Mar. 2026 was kr0.49. Hence, Cessatech AS's PB Ratio of today is 21.31.
The historical rank and industry rank for Cessatech AS's PB Ratio or its related term are showing as below:
XSAT:CESSA'
s PB Ratio Range Over the Past 10 Years
Min: 12.24 Med: 24.11 Max: 58.18
Current: 21.33
During the past 6 years, Cessatech AS's highest PB Ratio was 58.18. The lowest was 12.24. And the median was 24.11.
XSAT:CESSA's PB Ratio is ranked worse than 94.14% of 1228
companies
in the Biotechnology industry
Industry Median: 2.765
vs XSAT:CESSA: 21.33
During the past 12 months, Cessatech AS's average Book Value Per Share Growth Rate was 92.90% per year.
During the past 3 years, the average Book Value Per Share Growth Rate was -27.70% per year.
During the past 6 years, the highest 3-Year average Book Value Per Share Growth Rate of Cessatech AS was -27.70% per year. The lowest was -52.00% per year. And the median was -39.85% per year.
The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.
Be Aware
Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.
Cessatech AS PB Ratio Related Terms
Cessatech AS PB Ratio Historical Data
* Premium members only.
The historical data trend for Cessatech AS's PB Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
XSAT:CESSA vs VRTX, REGN, RVMD: PB Ratio Comparison
For the Biotechnology subindustry, Cessatech AS's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Cessatech AS PB Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Cessatech AS's PB Ratio distribution charts can be found below:
* The bar in red indicates where Cessatech AS's PB Ratio falls into.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.
Cessatech AS's PB Ratio for today is calculated as follows:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.
Cessatech AS (XSAT:CESSA) has a PB Ratio of 21.31 as of Aug. 04, 2026. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Cessatech AS and its competitors. This is 12% below median its historical median of 24.11. Over the past decade, Cessatech AS's PB Ratio has ranged from 12.24 to 58.18. According to the industry distribution chart, Cessatech AS ranks #1156 out of 1228 companies in the Biotechnology industry, placing it in the top 94.1%.
Is Cessatech AS's PB Ratio too high?
Cessatech AS's current PB Ratio of 21.31 is 12% below median its 10-year median of 24.11. Over the past 10 years, this metric has ranged from a low of 12.24 to a high of 58.18. The Biotechnology industry median PB Ratio is 2.77. Cessatech AS's value of 21.31 is 670.7% above this industry median. Based on the distribution chart, Cessatech AS ranks #1156 out of 1228 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Cessatech AS has a GF Score™ of 28/100, reflecting its overall financial health beyond just this single metric.
How does Cessatech AS's PB Ratio compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Cessatech AS ranks #1156 out of 1228 companies for PB Ratio. This places Cessatech AS in the lower half of its industry. The industry median PB Ratio is 2.77. Cessatech AS's value of 21.31 is 670.7% above this benchmark. Historically, Cessatech AS's own PB Ratio has ranged from 12.24 to 58.18 over the past decade. While the company's 10-year median is 24.11 vs. the industry median of 2.77, Cessatech AS has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PB Ratio for a Biotechnology company?
The median PB Ratio among Biotechnology companies is 2.77, based on 1,228 companies in the industry. Companies in the top quartile (top 25%) have a PB Ratio significantly above this median, while those in the bottom quartile fall well below. However, PB Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Cessatech AS's current PB Ratio of 21.31 is 670.7% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PB Ratio mean?
A high PB Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Cessatech AS and its competitors. For the Biotechnology industry, the median PB Ratio is 2.77 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Cessatech AS's current PB Ratio is 21.31, which is 12% below median its own 10-year median of 24.11. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cessatech AS stock overvalued right now?
Cessatech AS (XSAT:CESSA) has a current PB Ratio of 21.31. The current PB Ratio is 21.31, which is 12% below median its 10-year median of 24.11 and 670.7% above the Biotechnology industry median of 2.77. Cessatech AS's overall GF Score™ is 28/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PB Ratio calculated?
PB Ratio is calculated from a company's financial statements. For Cessatech AS (XSAT:CESSA), the current PB Ratio is 21.31 as of Aug. 04, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Cessatech AS is a pharmaceutical company committed to developing and commercializing evidence-based medicines for children for the treatment of paediatric acute pain. The company is advancing a pipeline comprising three assets, all addressing an unmet medical need in the treatment of children. The main candidate, CT001, a fixed-dose nasal spray for treating acute pain in children, is in the pre-launch phase in the U.S. and the EU. CT002, a non-invasive intranasal sedation for children undergoing medical procedures (e.g., MRI scans), has an approved PIP in the EU. CT003, a topical anaesthetic, is currently in pre-clinical development.
28GF Score
Get the complete analysis for XSAT:CESSA
PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XSAT:CESSA has been successfully added to your 
